Abstract
Omalizumab is currently approved for treatment of asthma and chronic idiopathic urticaria. Its mechanism of action involves the binding of free IgE in serum and preventing IgE binding to mast cells, preventing mast cell mediator release with the potential to treat mast cell disorders. Here we present a case of mast cell activation syndrome (MCAS) responding to treatment with omalizumab.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
